Key Highlights

• Regenxbio earned a $100.0 million milestone from AbbVie Global Enterprises Ltd. Under their collaboration agreement.

• The payment is tied to the inaugural dosing in a Phase IIb/III trial of surabgene lomparvovec for diabetic retinopathy.

• The cash receipt is projected for July 2026, following the June 29 filing with the SEC.

Regenxbio Inc. (NASDAQ: RGNX) announced on June 29 2026 that it has secured a $100.0 million milestone from AbbVie Global Enterprises Ltd. A subsidiary of AbbVie Inc. The payment follows the first administration of the company’s investigational gene‑therapy product in a pivotal trial for diabetic retinopathy.

Collaboration Framework

The milestone stems from a Collaboration and License Agreement originally signed on September 10 2021 and later amended on August 5 2025. The agreement outlines performance‑based payments linked to clinical progress, with the current tranche triggered by patient dosing.

Clinical Milestone Details

The trial, designated Phase IIb/III, evaluates surabgene lomparvovec (sura‑vec, ABBV‑RGX‑314) delivered via a suprachoroidal route. Dosing the first participant marks a critical transition toward late‑stage data collection, a step that directly activated the $100.0 million milestone.

Financial Impact

Regenxbio expects the cash to be received in July 2026, strengthening its balance sheet ahead of later trial phases. The infusion of funds complements existing capital resources and may support ongoing development activities without immediate equity dilution.

Regulatory Filing

The milestone disclosure appears in a Form 8‑K filing with the U.S. Securities and Exchange Commission, satisfying reporting obligations under the Securities Exchange Act of 1934. The filing confirms the transaction and provides the timeline for payment receipt.

Market Outlook

Investors will monitor the upcoming trial readouts, as they will determine further commercial potential for the eye‑gene therapy platform. The secured payment underscores AbbVie’s confidence in the partnership and may influence sentiment toward RGNX shares.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.